Summary The serum diagnostic value of the foeto-acinar pancreatic protein (FAP protein), an oncofoetal pancreatic antigen, was tested in 201 patients. Of these, 112 suffered from malignant disease (57 patients had pancreatic carcinoma and 55, extra-pancreatic malignancies) and 89 had benign disease (49 patients with hepato-pancreato-biliary disease and 40 with other benign disease). FAP protein was measured by a competitive radioimmunoassay. In this technique, the normal cut-off level was 10% inhibition. This was deducted from values in 32 normal sera. FAP protein levels superior to 10% inhibition were found in 86% of patients with pancreatic cancer, in 31% with non-pancreatic malignancy, in 69% with benign hepatopancreato-biliary disease and in 20% with other benign diseases. Accordingly, sensitivity of FAP protein for pancreatic carcinoma was 86% and specificity, 66%. However, high FAP protein levels (>30% inhibition) were almost exclusively seen in patients with pancreatic cancer. At this cut-off level, specificity increased to 95% but sensitivity decreased to 51%. Determination of the carbohydrate antigen CA19/9 was made in parallel by a commercially available assay. At the cut-off level of 37uml-1, CAl9/9 in our serum panel had a sensitivity of 74% for pancreatic carcinoma and a specificity of 88%. In pancreatic cancer 55 out of 57 patients had elevated levels of either FAP protein or CA19/9 (sensitivity; 96%).
The incidence of carcinoma of the pancreas appears to be increasing, but early diagnosis of this tumour is still difficult (Trede, 1985) , even after the introduction of modern procedures such as endoscopic retrograde cholangiopancreatography (ERCP) , percutaneous transhepatic cholangiography (PTC), computerized tomography (CT) and ultrasonographic examination (Go et al., 1981; Moossa & Levin, 1981) . Pancreatic cancer is usually far advanced by the time a patient becomes symptomatic, therefore, a 'screening' serum test for early detection would be of great clinical utility.
Pancreas specific antigens of an oncofoetal character were first described in the Syrian golden hamster (Benedi ct al., 1984) and later it was found that comparable antigens exist in man . Using SDS-PAGE, the principal antigens in man had a relative molecular weight of 60 kd and 110 kd. A murine monoclonal antibody recognizing the 110 kd exclusively has recently been produced . This antigen was characterized as a glycoprotein that binds to concanavalin A and is specific for pancreatic acini. By immunohistology, this protein exhibits an oncofoetal character, because maximal expression occurs at 20 weeks gestational age and gradually falls thereafter to remain at a low level in the adult organ (Albers et al., 1987) . Accordingly, the term foeto acinar pancreatic (FAP protein) was adopted. Also by histology, FAP protein was found to be strongly reexpressed in pancreatic carcinoma mostly in peritumoural areas as well as to a lower extent in chronic pancreatitis around inflammation areas. Using nitrocellulose blots and competitive RIA, FAP protein was shown-to be present in the serum of the majority of patients with cancer of the pancreas and was absent in nearly all other malignancies. However, FAP protein elevation was also observed in benign diseases of the pancreas .
Carbohydrate antigen CAl9/9 is, so far, the most widely used marker for pancreatic carcinoma, because, although it is not absolutely specific for pancreatic cancer it reliably distinguishes benign and malignant pathology (Ritts et al., 1984; Tatsuta et al., 1985) .
The purpose of the present study was to test the diagnostic value of the FAP protein combined with CA19/9 in patients with pancreatic disease and various other clinical control groups.
-10 bands including the 1 10kd FAP protein. Immune spleen cells were fused with SP2/0 cells (Buttin et al., 1976) . Hybridomas were selected by restricted specificity for foetal pancreas in a nitrocellulose assay (Escribano et al., 1983; Hawkes et al., 1982) and by immunohistology. Column, Pharmacia). A total of 1-1.5ml was collected having a specific radioactivity of 6 x 104 cpm 1-1 (inter-experiment range; 5.8-6.2 x 104 cpm).
Radioimmunometric assay Polypropylene beads (Oris, Saclay, France) were coated with monoclonal antibody J28 as follows: J28 ascites, diluted 1/300 in PBS was allowed to react with solid beads for 18 h at 4"C. Afterwards, the beads were incubated in I % BSA for 3 h at 4°C in order to neutralize remaining active sites. They were then washed with PBS, dried at 37°C and stored at 4'C.
Fixation of the 125I-SP4 was achieved as follows: Coated beads were placed in 60 x 10mm flat-bottomed test tubes (one bead per tube). Then, 300,u1 225I-SP4 serially diluted in 2% BSA (radioactivity range; 7.5 x 103-1.0 x 105 cpm) were added. After 2h incubation at 4°C, beads were washed 3 times with 6ml PBS/Tween (1000/1) and the radioactivity counted in a LKB gamma counter.
Inhbition assay J28 coated beads were preincubated with samples to be tested for 18 h. Then a constant amount of 125 I-SP 4 was added and radioactivity was counted after 2 h incubation and 3 washes in PBS as described above. Background was determined as the radioactivity fixed in beads coated with 2% BSA alone. The standard inhibition curve was established using serial dilutions of cold SP 4 in 2% BSA (final volume 30Opl per bead). In the case of sera, beads were pre-incubated with 100 pl serum diluted to 300 pl with PBS.
Measurement of CA 19/9 Sera were assayed with a solid phase radioimmunoassay using a commercially available kit (ELSA, CA19/9 Kit, Oris, Saclay, France). The upper limit of the normal range was determined as 37 u ml -1 (Del Villano et al., 1983) . All sera in our control normal group (group 0, n = 32) had values below this point.
Results
Validity of the RIA inhibition assay for FA P protein determination In order to determine the amount of FAP protein present in blood, a radioimmunoassay was developed. Radiolabelled antigen in all experiments was pancreatic cystic fluid (SP4) and FAP protein was evaluated by inhibition of the fixation of this fluid to Mab J28 coated beads. Because of the specificity of this monoclonal antibody only FAP protein was measured in the molecular heterogeneous fluid.
Fixation of 1 25I-SP4 Fixation of 1211-SP4 to Mab J28 coated beads was linear when the amount of added 125I-SP4 varied between 7x 103 and 7 x 104 cpm. The fixation rate was on average 8% of the added radioactivity (7.3%-9.6%). For values of 1251I-SP4 >7 x 104 cpm, fixation reached a plateau at 5.5 x 103 cpm.
Inhibition by cold pancreatic cystic fluid (SP4) SP4 was diluted 1/20 in 2% BSA. Fifty percent inhibition was obtained with lOpl of this dilution corresponding to 50 ng FAP. Maximal inhibition rate was 65%.
Inhibition in serum We tested 112 sera from malignant disease, 89 from benign disease and 32 from healthy subjects. All sera were analyzed in triplicate and values expressed as mean cpm. In negative inhibition controls, serum was replaced by 2% BSA. The inhibition rate was not dependent on the total radioactivity added, using values between 3.5 and 4.5 x 104 cpm. In a typical experiment, when 3.8 x 104 cpm were added, the mean fixation value after incubation with 2% BSA was 3,240 cpm and the background, 90 cpm.
Percentage This corresponds to an inhibition of 9.7%. Ten percent inhibition was thus taken as the normal cut-off level.
FAP protein assay in serum Mean values of radioactivity fixed to Mabs coated beads after inhibition by all sera, inhibition range and significance are given in Table I to show the liability of our assay.
Evaluation of the FAP protein and CA 19/9 in benign disease (Groups I and II) Group I (n=40) FAP protein: Most of the patients (80.0%) had FAP protein values within the normal range, and 20% showed moderate elevation; i.e. in 7 cases inhibition was <20% and one patient gave an inhibition of 26% (Table II) . This patient had a gastric ulcer suspected of penetrating the pancreas.
CAI9/9 Thirty-nine of 40 patients (97.5%) had a level FAP PROTEIN AND CA-19/9 IN PANCREATIC CANCER 497 (Table III) . CAl9/9 In 43 (78.2%) CAI9/9 levels were <37 uml-1, in 5 (9.1%) between 37 and 100uml-1 and in 7 (12.7%) >100uml-1 (Table III) (Figure 2 ).
Comparison of FAP protein and CA 19/9 in malignant disease (Groups III and IV) In cancer patients (n = 112), the FAP protein assay had a higher sensitivity (86%) than that of CA19/9 (74%) for pancreatic cancer. Specificity of the FAP protein assay was 69% (cut-off point: 10% inhibition) and 98% (cut-off point: 30% inhibition). Compared to this, the specificity of CAl9/9 was 78% (cut-off point: 37uml-1) and 87% (cut-off point: lOOuml-1).
Among the 15 pancreatic cancer patients (26%) negative for CA19/9, 9 had moderately elevated FAP protein and 4, high elevation. On the contrary in eight FAP proteinnegative cases, 6 were positive for CA19/9. As a result only 2 patients were negative for both markers i.e. in 55/57 (96%) at least one marker was elevated (Figure 2 ). Sensitivity and specificity of FAP protein and CA 19/9 for pancreatic carcinoma
The assay parameters for all sera (n=233) for both markers either alone or combined are summarized in Table IV . It can be seen in particular that very high sensitivity (96%) is obtained in the combined test.
Discussion
Earlier studies have shown that expression of FAP protein rises strongly in pathological conditions of the pancreas, in particular, neoplasia. Elevated production together with necrosis of pancreatic tissue and/or dysfunction in the metabolism of this protein could explain why it circulates in the blood in the case of pancreatic pathology but not under physiological conditions. Figure 2 Combined analysis of FAP protein and CA 19/9 serum levels. Groups are the same as in Figure 1 . Each value corresponds to a single patient. CA19/9 values are separated into negative (<37uml-1), moderate (37-100uml-1) and high ( > I00 u ml-1) levels on the abcissa. In the present study, we investigated the diagnostic value of FAP protein in comparison with that of the carbohydrate antigen CA19/9 and the combination of both markers. As in previous work, FAP protein was determined here by competition RIA using a normal cut-off level at 10% inhibition instead of the former 5%. In pathology a second cut-off point at 30% inhibition was considered because values above this were found almost exclusively in pancreatic carcinoma.
Levels greater than 10% inhibition were observed in 86% of cancers of the pancreas, 69% of benign hepato-pancreatobiliary diseases, 31% of other cancers and 20% of other benign diseases. In the latter two groups all patients had moderate FAP protein elevation (under 20% inhibition) except two lung cancer patients (32% and 21% inhibition) and one with gastric ulcer suspected of penetrating the pancreas (26% inhibition).
By immunohistology, expression of FAP protein was found to be confined to the exocrine pancreas. Other organs including liver and biliary tissue, either normal or pathological, were uniformly negative . This suggests that serum positivity in non-pancreatic disease might be the result of alteration of the excretion of this protein in the pancreas. At the cut-off point of 10% inhibition, sensitivity of the FAP protein serum assay for pancreatic pathology was 79% and specificity 80%; for pancreatic carcinoma the corresponding values were 86% and 66%, respectively. In previous reports (Albers Escribano et al., 1987) sensitivity for cancer of the pancreas was slightly superior (94%). The difference can be explained by the choice of cut-off point and by the fact that the sera in the two studies were not identical.
Sera from 29 patients with pancreatic carcinoma (51%), 5 with chronic pancreatitis (18%) and only one patient in each of the groups liver cirrhosis, biliary disease and extrapancreatic cancer gave inhibition values in excess of 30%. At this cut-off point specificity for cancer of the pancreas was very high (95%) but sensitivity fell to 51% because about 50% of patients in both cancer of the pancreas and benign hepato-pancreato-biliary diseases were in the 10-30% inhibition range.
Our analysis of CAI9/9 again confirms the good differential diagnostic capacity of this marker in malignancy over benign disease. In the latter group the cut-off point of 37uml-1 was exceeded in only 9 patients (10%). Of these, 8 were in the middle range ( <100 u ml -1). In malignancy, 74% of pancreatic cancers and 22% of other cancers had elevated levels of CAl9/9. Therefore, sensitivity for pancreatic cancer was 74% and specificity, 88%. Specificity is higher than in other reports probably because all patients with nonpancreatic malignancies in this study had no metastases, but sensitivity is in good concordance with previously reported results (Gupta et al., 1985; Haglund et al., 1986) . It remains to be seen whether absence of metastasis in this group would also affect the FAP protein specificity.
The combined assay of FAP protein and CA] 9/9 provided a test which was almost absolute for cancer of the pancreas. Of the 35 patients positive for FAP protein in group II only 4 had elevated CAI9/9. Additionally 2 FAP protein negative patients showed moderate elevation of this marker. One patient with chronic pancreatitis had high levels of both markers that could indicate suspicion of malignancy.
In cancer of the pancreas all except 2 patients revealed elevation of one or other of the markers (sensitivity 96%). The sensitivity of CEA combined with CA19/9 was reported to be 88% (Gupta et al., 1985) or 85% (Haglund et al., 1986) i.e. lower than in our study.
It is of interest that 13 pancreatic cancer patients with normal CA 19/9 values had elevated FAP protein against only 8 FAP protein negative and CA19/9 positive. These results show that FAP protein is not only more specific than CA 19/9 in discriminating amongst cancer sites (only one extra-pancreatic cancer gave 31% inhibition in the FAP protein assay against 6 with CA 19/9 values > 1O00 uml -1) but that, furthermore, the overall sensitivity for pancreatic carcinoma is higher.
A correlation between tumour stage of pancreatic carcinoma and CA19/9 levels has been reported (Safi et al., 1986; Tatsuta et al., 1985) . In this study the stage of pancreatic carcinoma was unknown. Studies in experimental carcinogenesis of the pancreas (Escribano et al., 1985; Eriguchi et al., 1987) have revealed that foetal pancreatic antigens appear before microscopic tumours can be detected, suggesting that they could serve as markers at a preclinical stage. A follow up study is now required to correlate FAP protein levels and extension of pancreatic tumour.
Adenocarcinoma of the exocrine pancreas is among the most lethal and difficult to treat of all malignancies. The survival of even curatively resected patients is still very poor.
The specificity of diagnostic techniques for early-stage carcinoma of the pancreas is still disappointingly low. Early detection would improve the chance of curative surgery. If pancreatic disease were detected by a screening test, it might not be difficult to diagnose even small cancers by modern methods such as ERCP, PTC (Freeny & Ball, 1981) , echography lishi et al., 1986) , CT scan (Sakahara et al., 1986) , angiography (Rosch & Keller, 1981) , and other clinical and laboratory findings. Therefore, the most important and difficult problem is detection of pancreatic pathology in asymptomatic patients. For this reason, a reliable and specific screening test for pancreatic disease would be a significant advance. Because of the high sensitivity of FAP protein for pancreatic carcinoma and its excellent specificity for pancreatic pathology, this new marker could be of potential utility in early clinical diagnosis. We are planning such a test in a selected population.
